NCT00631540

Brief Summary

The purpose of the study is to evaluate the safety and effectiveness of the Formula Balloon-Expandable Stent in treatment of renal artery stenosis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2008

Longer than P75 for not_applicable

Geographic Reach
1 country

7 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2008

Completed
27 days until next milestone

First Submitted

Initial submission to the registry

February 28, 2008

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 7, 2008

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
1 year until next milestone

Results Posted

Study results publicly available

May 19, 2011

Completed
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2012

Completed
Last Updated

December 16, 2013

Status Verified

November 1, 2013

Enrollment Period

2.2 years

First QC Date

February 28, 2008

Results QC Date

February 11, 2011

Last Update Submit

November 21, 2013

Conditions

Keywords

renal artery stenosishypertensionrenovascularrenal artery blockagerenal artery diseaserenal arteriesangioplasty renal arteryrenal artery stentrenal artery dopplerrenovascular hypertensionkidney stenosisrenal arterystentstentingkidney diseaserenal failureatherosclerosisarterial hypertensionstenosis

Outcome Measures

Primary Outcomes (1)

  • Primary Patency of the Treated Renal Artery

    Based on ultrasound images assessed by core lab.

    9 Months

Secondary Outcomes (5)

  • Number of Participants With 30-day Major Adverse Events

    30 Days

  • Number of Participants With 9-month Major Adverse Events

    9 Months

  • Technical Success

    Prior to Discharge

  • Acute Procedural Success

    Prior to Discharge

  • 30-day Clinical Success

    30 Days

Study Arms (1)

1

EXPERIMENTAL

renal artery stenting

Device: Formula Balloon-Expandable Stent

Interventions

renal artery stenting

Also known as: renal artery revascularization
1

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • renal artery stenosis
  • appropriate size and location of the lesion
  • suboptimal angioplasty

You may not qualify if:

  • less than 18 years old
  • failure or inability to give informed consent
  • simultaneously participating in another drug or device study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

Munroe Regional Medical Center

Ocala, Florida, 34471, United States

Location

Orlando Regional Medical Center

Orlando, Florida, 32806, United States

Location

Lenox Hill Hospital

New York, New York, 10075, United States

Location

Wake Med Raleigh Campus

Raleigh, North Carolina, 27610, United States

Location

Fairfield Medical Center

Lancaster, Ohio, 43130, United States

Location

Pinnacle Health at Harrisburg

Harrisburg, Pennsylvania, 17110, United States

Location

Swedish Medical Center

Seattle, Washington, 98122, United States

Location

Related Publications (1)

  • Bersin RM, Ansel G, Rizzo A, Bob Smouse H, Sinha S, Sachar R, Dave R, Weinstock BS, Feldman R, Roubin GS. Nine-month results of the REFORM study: a prospective, single-arm, multicenter clinical study of the safety and effectiveness of the Formula balloon-expandable stent for treatment of renal artery stenosis. Catheter Cardiovasc Interv. 2013 Aug 1;82(2):266-73. doi: 10.1002/ccd.24481. Epub 2013 Mar 25.

MeSH Terms

Conditions

Renal Artery ObstructionHypertensionHypertension, RenovascularKidney DiseasesRenal InsufficiencyAtherosclerosisConstriction, Pathologic

Condition Hierarchy (Ancestors)

Urologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesArterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesHypertension, RenalArteriosclerosisPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Scott Snyder, PhD
Organization
Cook Incorporated

Study Officials

  • Robert Bersin, MD

    Swedish Medical Center

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
GT60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 28, 2008

First Posted

March 7, 2008

Study Start

February 1, 2008

Primary Completion

May 1, 2010

Study Completion

May 1, 2012

Last Updated

December 16, 2013

Results First Posted

May 19, 2011

Record last verified: 2013-11

Locations